Compare RGS & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RGS | PRLD |
|---|---|---|
| Founded | 1922 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 71.3M | 69.1M |
| IPO Year | 1991 | 2020 |
| Metric | RGS | PRLD |
|---|---|---|
| Price | $27.39 | $2.45 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 5.3K | ★ 429.6K |
| Earning Date | 02-11-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 20.05 | N/A |
| EPS | ★ 45.08 | N/A |
| Revenue | ★ $223,032,000.00 | $10,500,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.65 | ★ N/A |
| Revenue Growth | 13.98 | ★ 250.00 |
| 52 Week Low | $15.00 | $0.61 |
| 52 Week High | $31.50 | $4.22 |
| Indicator | RGS | PRLD |
|---|---|---|
| Relative Strength Index (RSI) | 41.51 | 68.38 |
| Support Level | $28.04 | $1.90 |
| Resistance Level | $30.17 | $2.38 |
| Average True Range (ATR) | 0.83 | 0.19 |
| MACD | -0.10 | 0.07 |
| Stochastic Oscillator | 0.00 | 96.12 |
Regis Corporation owns, franchises, and operates beauty salons in North America and the U.K., serving mainly price-conscious customers. Its salons, located mostly in strip malls, shopping centers, and Walmart stores, offer services like haircutting, styling, shampooing, conditioning, and hair coloring, along with hair care and beauty products. The company's primary brands include Supercuts, SmartStyle, and Cost Cutters. Regis generates the majority of its revenue from these mass-market locations and reports operations in two segments: franchise and company-owned, with services making up about 94% of company-owned salon sales.
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.